Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BGI Genomics Climbs 44% after $81 Million Shenzhen IPO

publication date: Jul 14, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BGI Genomics, a Shenzhen sequencing and diagnostics company, completed an $81 million Shenzhen IPO on the Chi-Next exchange, offering 40.1 million shares at 13.64 RMB per share. BGI surged in open market trading, rising 32% to an initial limit, where it was halted temporarily, and then climbing further to 19.64 RMB per share. The closing quote represented a 44% increase over the IPO price, the limit for an opening day in Shenzhen. At the IPO price, BGI's valuation was $802 million, which rose to $1.15 billion at the close of trading. More details...

Stock Symbol: (SHZ: 300676)

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...